The gut microbiota and inflammatory bowel disease

Current Opinion in Rheumatology

Volumn 27, Issue 4, 2015, Pages 388-396

  Goto, Yoshiyuki ^a,b   Kurashima, Yosuke ^a   Kiyono, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Commensal microbiota; Dysbiosis; Fecal microbiota transplantation; Innate lymphoid cells; Mast cells

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; PREBIOTIC AGENT; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BIFIDOBACTERIUM BREVE; CLINICAL FEATURE; CLINICAL PRACTICE; COMMENSALISM; CROHN DISEASE; DENDRITIC CELL; DYSBIOSIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS GALLINARUM; FECES MICROFLORA; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE MUCOSA; LYMPHOID CELL; MAST CELL; MICROBIAL COMMUNITY; MICROFLORA; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; REVIEW; TH17 CELL; BACTERIUM; FECAL MICROBIOTA TRANSPLANTATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; MUCOSAL IMMUNITY; PROCEDURES; SYMBIOSIS;

BACTERIA; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; SYMBIOSIS;

EID: 84942564274     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000192     Document Type: Review

References (86)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
2. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
3. Goto Y, Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev 2012;245:147-163.
4. Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008;134:743-756.
5. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008;456:259-263.
6. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008;456:264-268.
7. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014;40:843-854.
8. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013;500:232-236.
9. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337-341.
10. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009;31:677-689.
11. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-498.
12. Goto Y, Ivanov II. Intestinal epithelial cells as mediators of the commensal-host immune crosstalk. Immunol Cell Biol 2013;91:204-214.
13. Kajino-Sakamoto R, Inagaki M, Lippert E, et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol 2008;181:1143-1152.
14. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-561.
15. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011;469:543-547.
16. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011;9:265-278.
17. Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008;105:15064-15069.
18. Van Der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117-129.
19. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002;295:1726-1729.
20. Nishida A, Lau CW, Zhang M, et al. The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice. Gastroenterology 2012;142:865-874; e862.
21. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004;4:953-964.
22. Vaishnava S, Behrendt CL, Ismail AS, et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A 2008;105:20858-20863.
23. Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin RegIIIg promotes the spatial segregation of microbiota and host in the intestine. Science 2011;334:255-258.
24. Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol 2003;4:269-273.
25. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal hostmicrobial relationships in the intestine. Science 2001;291:881-884.
26. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718-6724.
27. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-734.
28. Sanos SL, Bui VL, Mortha A, et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol 2009;10:83-91.
29. Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006;313:1126-1130.
30. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
31. Comstock LE, Kasper DL. Bacterial glycans: key mediators of diverse host immune responses. Cell 2006;126:847-850.
32. Hooper LV, Xu J, Falk PG, et al. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci U S A 1999;96:9833-9838.
33. Imbert-Marcille BM, Barbe L, Dupe M, et al. A FUT2 gene common polymorphism determines resistance to rotavirus A of the P [8] genotype. J Infect Dis 2014;209:1227-1230.
34. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003;9:548-553.
35. Chessa D, Winter MG, Jakomin M, Baumler AJ. Salmonella enterica serotype Typhimurium Std fimbriae bind terminal alpha (1, 2) fucose residues in the cecal mucosa. Mol Microbiol 2009;71:864-875.
36. Kashyap PC, Marcobal A, Ursell LK, et al. Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiota. Proc Natl Acad Sci U S A 2013;110:17059-17064.
37. Rausch P, Rehman A, Kunzel S, et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci U S A 2011;108:19030-19035.
38. Goto Y, Obata T, Kunisawa J, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 2014;345:1254009.
39. Pham TA, Clare S, Goulding D, et al. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 2014;16:504-516.
40. Smyth DJ, Cooper JD, Howson JM, et al. FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection. Diabetes 2011;60:3081-3084.
41. Folseraas T, Melum E, Rausch P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012;57:366-375.
42. Pickard JM, Maurice CF, Kinnebrew MA, et al. Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 2014;514:638-641.
43. Umesaki Y, Setoyama H, Matsumoto S, et al. Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun 1999;67:3504-3511.
44. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011;108(Suppl 1):4615-4622.
45. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32:815-827.
46. Goto Y, Panea C, Nakato G, et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 2014;40:594-607.
47. Yang Y, Torchinsky MB, Gobert M, et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 2014;510:152-156.
48. Jang MH, Kweon MN, Iwatani K, et al. Intestinal villousMcells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A 2004;101:6110-6115.
49. Rescigno M, Urbano M, Valzasina B, et al. Ricciardi-Castagnoli P: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361-367.
50. Morton AM, Sefik E, Upadhyay R, et al. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl Acad Sci U S A 2014;111:6696-6701.
51. Kinnebrew MA, Buffie CG, Diehl GE, et al. Interleukin 23 production by intestinal CD103 (+) CD11b (+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity 2012;36:276-287.
52. Tumanov AV, Koroleva EP, Guo X, et al. Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe 2011;10:44-53.
53. Buonocore S, Ahern PP, Uhlig HH, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010;464:1371-1375.
54. Leppkes M, Becker C, Ivanov II, et al. ROR (-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136:257-267.
55. Obata T, Goto Y, Kunisawa J, et al. Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibodymediated symbiosis. Proc Natl Acad Sci U S A 2010;107:7419-7424.
56. Sonnenberg GF, Monticelli LA, Alenghat T, et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 2012;336:1321-1325.
57. Hironaka I, Iwase T, Sugimoto S, et al. Glucose triggers ATP secretion from bacteria in a growth-phase-dependent manner. Appl Environ Microbiol 2013;79:2328-2335.
58. Kusu T, Kayama H, Kinoshita M, et al. Ecto-nucleoside triphosphate diphosphohydrolase 7 controls Th17 cell responses through regulation of luminal ATP in the small intestine. J Immunol 2013;190:774-783.
59. Proietti M, Cornacchione V, Rezzonico Jost T, et al. ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer's patches to promote host-microbiota mutualism. Immunity 2013;41:789-801.
60. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012;209:1241-1253.
61. Yao Y, Levings MK, Steiner TS. ATP conditions intestinal epithelial cells to an inflammatory state that promotes components of DC maturation. Eur J Immunol 2012;42:3310-3321.
62. Schenk U, Westendorf AM, Radaelli E, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 2008;1:ra6.
63. Kurashima Y, Amiya T, Nochi T, et al. Extracellular ATP mediates mast celldependent intestinal inflammation through P2X7 purinoceptors. Nat Commun 2012;3:1034.
64. Marques CC, Castelo-Branco MT, Pacheco RG, et al. Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. Biochim Biophys Acta 2014;1842:65-78.
65. Neves AR, Castelo-Branco MT, Figliuolo VR, et al. Overexpression of ATPactivated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn's disease. Inflamm Bowel Dis 2014;20:444-457.
66. Matsukawa T, Izawa K, Isobe M, et al. Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation. Gut 2014;
67. Gut. 2015 Feb. 11. pii: gutjnl-2014-308900. doi: 10.1136/gutjnl-2014-308900. [Epub ahead of print]
68. Chandel S, Prakash A, Medhi B. Current scenario in inflammatory bowel disease: drug development prospects. Pharmacol Rep 2015;67:224-229.
69. Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest 2014;124:4190-4196.
70. Chen WX, Ren LH, Shi RH. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol 2014;20:15657-15663.
71. Scaldaferri F, Gerardi V, Lopetuso LR, et al. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013;2013:435268.
72. Kwon HK, Lee CG, So JS, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A 2010;107:2159-2164.
73. Macho Fernandez E, Pot B, Grangette C. Beneficial effect of probiotics in IBD: are peptidogycan and NOD2 the molecular key effectors? Gut Microbes 2011;2:280-286.
74. Hormannsperger G, Von Schillde MA, Haller D. Lactocepin as a protective microbial structure in the context of IBD. Gut Microbes 2013;4:152-157.
75. Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc 2014;73:490-497.
76. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-1664.
77. Jeon SG, Kayama H, Ueda Y, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 2012;8:e1002714.
78. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients 2013;5:1417-1435.
79. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-1633.
80. Simpson HL, Campbell BJ, Rhodes JM. IBD: microbiota manipulation through diet and modified bacteria. Dig Dis 2014;32(Suppl 1):18-25.
81. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446-450.
82. Zeng H, Chi H. Metabolic control of regulatory T cell development and function. Trends Immunol 2015;36:3-12.
83. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacteriumprausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014;63:1275-1283.
84. Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013;108:177-185.
85. Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015;21:102-111.
86. Mayer EA, Tillisch K, Gupta A. Gut-brain axis and the microbiota. J Clin Invest 2015;125:926-938.